Back to Intra-day news
Intra-day news

[創新醫藥]創新醫藥]板塊再起動,留意信藥購15446/康方15723/ 中藥購15445/晶泰購16903

2026-09-21 11:48 Article
Intra-day news
Warning This article available in Chinese version only

 

創新醫藥股今早全線向好,消息面上,路透報導美國起草針對生物技術對華投資新規,但討論凡方案較此前主張的一刀切廣泛限制不同,不封禁全部氐物醫藥跨境交易,允許海外醫企收購及開展授權合作。

消息刺激內地創新藥股價急升,如投資者看好,可留意以下創新藥及相關股份的認購證部署。

信藥購15446之行使價為128.01元,2027年1 月到期,實際槓桿約5倍,引伸波幅約為62.5%;

康方購15723之行使價為128.26元,2027年7月到期,實際槓桿約2.75倍,引伸波幅約為74.6%;

中藥購15445之行使價為6.5元,2027年7月到期,實際槓桿約4.67倍,引伸波幅約為51%;

晶泰購16903之行使價為9.3元,2027年3月到期,實際槓桿約3.06倍,引伸波幅約為79%。

本結構性產品並無抵押品,如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。

本文由香港上海匯豐銀行有限公司(「本行」或「發行商」)發行(包括任何參考條款),僅供參考之用,並不構成邀約、游說、或建議出售或購買結構性產品。

結構性產品屬複雜產品,投資者務須就此審慎行事,除非投資者完全了解及願意承擔所涉風險,否則切勿投資此產品。結構性產品價格可急升可急跌,投資者或會損失所有或大部分投資。過往表現並不反映將來表現。投資前應了解結構性產品之性質及風險,並詳閱有關上市文件,獨立決定是否適合自己,若需要應諮詢專業建議。本行及其委任之流通量提供者可能是結構性產品的唯一市場參與者,而結構性產品的二級市場可能有限。謹請注意,牛熊證設有強制收回機制,因此有可能提早終止,在此情況下(i)N類牛熊證投資者會損失於牛熊證的全部投資;而(ii)R類牛熊證之剩餘價值則可能為零。買賣與美國指數掛鈎的結構性產品可能帶有額外風險,包括:(a)與交易日和交易時間差異有關的風險;(b) 有關指數的公開資料較少,或未有提供中文版本;(c) 與指數有關的政治和經濟風險(例如美國);(d) 匯率風險; (e) 可能延遲結算及(f) 在成份股並無交易時公佈指數水平與MSCI中國A50互聯互通指數掛鈎的衍生權證投資者可能會承受額外風險,包括:(i) 新推出指數的風險;(ii) 指數成份股為透過滬港通及/或深港通在滬港通及深港通的北向交易渠道買賣的A股;(iii) 有關指數的公開資料較少,且該等資料或未有提供中文版本;(iv) 與指數有關的政治及經濟風險;(v) 匯率風險;及(vi) 人民幣利率風險。

作者為金管局及證監會持牌人士,並無就結構性產品或相關資產持有任何直接或間接權益。

Other articles

Frequently used shortcut

Important Risk Warning

The structured products are not collateralized. If the issuer is insolvent or defaults, investors may not recover part or all of the amount due.

Structured products are complex products. Investors should exercise caution in relation to them. The price of the structured products may fall in value as rapidly as it may rise and investors may sustain a total or substantial loss of their investment. Prospective investors should ensure that they understand the nature and risks and seek professional advice where applicable. Please also note that CBBCs have a mandatory call feature and may therefore be subject to early termination, upon which (i) investors in category N CBBCs will lose all of their investments in the CBBCs; and (ii) the residual value of category R CBBCs may be zero. Trading structured products with United States (US) underlying index may be exposed to additional risks, including (a) risks relating to difference in trading days and hours, (b) less public information about the index and such information may not be available in Chinese, (c) political and economic risks relating to the index regions (such as the US), (d) exchange rate risks, (e) possible delay in settlement, (f) publication of index level when component shares are not trading, and (g) occurrence of mandatory call event for US index CBBCs outside trading hours. Click here for "Terms of Use".

Disclaimer

By viewing this website or using any information or functions of this website, you are deemed to acknowledge that you agree to the Privacy and Security, Terms of Use and Hyperlink Policy. Click here for "Disclaimer".

All data/charts are for reference purposes only.